Genetic progression of metastatic melanoma
- PMID: 15363539
- DOI: 10.1016/j.canlet.2004.06.049
Genetic progression of metastatic melanoma
Abstract
Melanoma progression is well defined in its clinical, histopathological and biological aspects, but the molecular mechanism involved and the genetic markers associated to metastatic dissemination are only beginning to be defined. The recent development of high-throughput technologies aimed at global molecular profiling of cancer is switching on the spotlight at previously unknown candidate genes involved in melanoma, such as WNT5A and BRAF. In fact, several tumor suppressors and oncogenes have been shown to be involved in melanoma pathogenesis, including CDKN2A, PTEN, TP53, RAS and MYC, though they have not been related to melanoma subtypes or validated as prognostic markers. Here, we have reviewed the published data relative to the major genes involved in melanoma pathogenesis, which may represent important markers for the identification of genetic profiles of melanoma subtypes.
Similar articles
-
Novel biomarkers in malignant melanoma.Clin Chim Acta. 2006 May;367(1-2):28-35. doi: 10.1016/j.cca.2005.10.029. Epub 2006 Feb 9. Clin Chim Acta. 2006. PMID: 16480699 Review.
-
Cutaneous melanoma susceptibility and progression genes.Cancer Lett. 2005 Dec 18;230(2):153-86. doi: 10.1016/j.canlet.2004.12.033. Cancer Lett. 2005. PMID: 16297704 Review.
-
Prognostic signs in melanoma: state of the art.J Eur Acad Dermatol Venereol. 2004 May;18(3):291-300. doi: 10.1111/j.1468-3083.2004.00895.x. J Eur Acad Dermatol Venereol. 2004. PMID: 15096138 Review.
-
Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction.Cancer. 2005 Oct 15;104(8):1678-86. doi: 10.1002/cncr.21372. Cancer. 2005. PMID: 16116595
-
Genetic alterations in signaling pathways in melanoma.Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s. doi: 10.1158/1078-0432.CCR-05-2518. Clin Cancer Res. 2006. PMID: 16609049 Review.
Cited by
-
Melanoma genetics and the development of rational therapeutics.J Clin Invest. 2005 Apr;115(4):813-24. doi: 10.1172/JCI24808. J Clin Invest. 2005. PMID: 15841168 Free PMC article. Review.
-
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.Neuro Oncol. 2008 Dec;10(6):946-57. doi: 10.1215/15228517-2008-053. Epub 2008 Jul 23. Neuro Oncol. 2008. PMID: 18650488 Free PMC article.
-
Assaying Wnt5A-mediated invasion in melanoma cells.Methods Mol Biol. 2008;468:243-53. doi: 10.1007/978-1-59745-249-6_19. Methods Mol Biol. 2008. PMID: 19099260 Free PMC article.
-
DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.Oncogene. 2012 Oct 11;31(41):4472-83. doi: 10.1038/onc.2011.623. Epub 2012 Jan 23. Oncogene. 2012. PMID: 22266849 Free PMC article.
-
Uveal vs. cutaneous melanoma. Origins and causes of the differences.Clin Transl Oncol. 2008 Mar;10(3):137-42. doi: 10.1007/s12094-008-0170-4. Clin Transl Oncol. 2008. PMID: 18321815 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous